Technically, he is not supposed to be buying if he knows something about XTClave that is not yet public information. Nevertheless it is difficult not to infer that Mr Slavich thinks the shares are good value at current prices.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025